Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases

Heart and Vessels

Volumn 27, Issue 4, 2012, Pages 344-351

  Ikemoto, Tomokazu ^a   Hojo, Yukihiro ^a   Kondo, Hideyuki ^a   Takahashi, Nozomu ^a   Hirose, Masahiro ^a   Nishimura, Yoshioki ^a   Katsuki, Takaaki ^a   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary intervention; Endothelium; Inflammation; Senescence

Indexed keywords

ENDOGLIN; HYDROGEN PEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CELL AGING; CELL STIMULATION; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE CONTROL; ENDOGLIN BLOOD LEVEL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE; SUDDEN DEATH; UMBILICAL VEIN ENDOTHELIAL CELL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTIGENS, CD; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL AGING; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION MEDIATORS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84864288370     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-011-0163-z     Document Type: Article

References (29)

1. Dallas N, Samuel S, Xia L, Fan F, Gray M, Lim S, Ellis L (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14:1931-1937 (Pubitemid 351551101)
2. McAllister K, Grogg K, Johnson D, Gallione C, Baldwin M, Jackson C, Helmbold E, Markel D, McKinnon W, Murrell J, McCormick M, Pericak-Vance M, Heutink P, Oostra B, Haitjema T, Westerman C, Porteous M, Guttmacher A, Letarte M, Marchuk D (1994) Endoglin, a TGF-bold beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351
3. Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, Lux A, McKinnon W, Marchuk D, Guttmacher A (2003) Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK 1 mutations. J Med Genet 40:585-590 (Pubitemid 37046911)
4. Govani F, Shovlin C (2009) Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 17:860-871
5. Piao M, Tokunaga O (2006) Significant expression of endoglin (CD105), TGFb-1 and TGFb R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb 13:82-89
6. Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, O'Shaughnessy C, Caputo R, Kereiakes D, Williams D, Teirstein P, Jaeger J, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323 (Pubitemid 37186209)
7. Holmes DR Jr, Leon M, Moses J, Popma J, Cutlip D, Fitzgerald P, Brown C, Fischell T, Wong S, Midei M, Snead D, Kuntz R (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:634-640 (Pubitemid 38198871)
8. Weisz G, Leon M, Holmes DR Jr, Kereiakes D, Clark M, Cohen B, Ellis S, Coleman P, Hill C, Shi C, Cutlip D, Kuntz R, Moses J (2006) Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47:1350-1355
9. Weisz G, Leon M, Holmes DR Jr, Kereiakes D, Popma J, Teirstein P, Cohen S, Wang H, Cutlip D, Moses J (2009) Five-year follow-up after sirolimus-eluting stent implantation: results of the SIRIUS (Sirolimus-Eluting Stent in de-novo Native Coronary Lesions) trial. J Am Coll Cardiol 53:1488-1497
10. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp M, Baumgart D, Seyfarth M, Pfisterer M, Schömig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030-1039 (Pubitemid 46376803)
11. Ninomiya J, L'Italien G, Criqui M, Whyte J, Gamst A, Chen R (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109:42-46 (Pubitemid 38056019)
12. Ledue T, Weiner D, Sipe J, Poulin S, Collins M, Rifai N (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannosebinding protein in human serum. Ann Clin Biochem 35:745-753 (Pubitemid 28523808)
13. Folland E, Parisi A, Moynihan P, Jones D, Feldman C, Tow D (1979) Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 60:760-766 (Pubitemid 10239332)
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated gfr from serum creatinine in Japan. Am J Kidney Dis 53:982-992
15. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y, Bdolah Y, Lim K, Yuan H, Libermann T, Stillman I, Roberts D, D'Amore P, Epstein F, Sellke F, Romero R, Sukhatme V, Letarte M, Karumanchi S (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642-649 (Pubitemid 43865232)
16. Richard J, Levine R, Lam C, Qian C, Yu K, Maynard S, Sachs B, Sibai B, Epstein F, Romero R, Thadhani R, Karumanchi S (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992-1005 (Pubitemid 44343543)
17. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M (2003) Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 3:427-432 (Pubitemid 38017479)
18. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, Boileau C, Allanore Y (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 47:972-975 (Pubitemid 351865917)
19. Conley B, Smith J, Guerrero-Esteo M, Bernabeu C, Vary C (2000) Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153:323-335 (Pubitemid 32120331)
20. Torsney E, Charlton R, Parums D, Collis M, Arthur H (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51:464-470 (Pubitemid 35034452)
21. Ma X, Labinaz M, Goldstein J, Miller H, Keon W, Letarte M, O'Brien E (2000) Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 20:2546-2552
22. Lebrin F, Goumans M, Jonker L, Carvalho R, Valdimarsdottir G, Thorikay M, Mummery C, Arthur H, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018-4028 (Pubitemid 39472423)
23. Li C, Bethell H, Wilson P, Bhatnagar D, Walker M, Kumar S (2000) The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 152:249-256
24. Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri M, Coli L, De Pasclis A, Lannelli S (2002) Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 61:324-335 (Pubitemid 34075160)
25. Foidart J, Schaaps J, Chantraine F, Munaut C, Lorquet S (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immuno 82:106-111
26. Blanco F, Grande M, Langa C, Oujo B, Velasco S, Rodriguez-Barbero A, Perez-Gomez E, Quintanilla M, López-Novoa J, Bernabeu C (2008) S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 103:1383-1392
27. Paquet M, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M (2001) Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 15:1347-1357 (Pubitemid 32640663)
28. Kimura H, Hiramitsu S, Miyagishima K, Mori K, Yoda R, Kato S, Kato Y, Morimoto S, Hishida H, Ozaki Y (2010) Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure. Heart Vessels 25:306-312
29. Coral-Alvarado P, Garces M, Caminos J, Iglesias-Gamarra A, Restrepo J, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol (Epub 2010 Aug 24)